Cover image for Vol. 121 Issue 13

Early View (Online Version of Record published before inclusion in an issue)

Edited By: Fadlo R. Khuri, MD

Impact Factor: 4.889

ISI Journal Citation Reports © Ranking: 2014: 32/211 (Oncology)

Online ISSN: 1097-0142

Associated Title(s): Cancer Cytopathology, CA: A Cancer Journal for Clinicians

  1. Editorial

    1. Does one size fit all? The updated ovarian cancer staging: Still a work in progress

      Linda R. Duska and Elise C. Kohn

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29521

      The International Federation of Gynecology and Obstetrics (FIGO) has recognized serous tubal intraepithelial carcinoma as a precursor lesion for high-grade serous epithelial ovarian cancer. Future staging systems should consider reclassifying stage based on tumor biologic behavior.

  2. Review Articles

    1. Are we missing an opportunity for cancer prevention? Human papillomavirus vaccination for survivors of pediatric and young adult cancers

      Sarah M. Temkin and Nita L. Seibel

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29515

      Despite the risks of human papillomavirus–related disease, the uptake of human papillomavirus vaccination among childhood and adolescent cancer survivors has been low. The human papillomavirus vaccines are safe and effective, and increasing provider endorsements of vaccination in this population is important.

  3. Original Articles

    1. Disease Site

      Gynecologic Oncology
      Abridged republication of FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum

      Jaime Prat and for the FIGO Committee on Gynecologic Oncology

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29524

      The current article is an abridged version of the staging classification for cancer of the ovary, fallopian tube, and peritoneum, originally published in the International Journal of Gynecology and Obstetrics in January 2014.

    2. Discipline

      Disparities Research
      Racial differences in breast cancer survival in a large urban integrated health system

      Molly E. Roseland, Mary E. Pressler, Lois E. Lamerato, Rick Krajenta, Julie J. Ruterbusch, Jason C. Booza, Kendra Schwartz and Michael S. Simon

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29523

      Racial differences in breast cancer survival can be explained by clinical and socioeconomic factors. African American women with breast cancer remain disproportionately affected by unfavorable tumor characteristics and economic deprivation, which likely contribute to their increased overall mortality.

  4. Correspondence

    1. Reply to treatment decisions and outcome in very elderly patients with diffuse large B-cell lymphoma

      Jessica N. Williams, Jean L. Koff and Christopher R. Flowers

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29508

      Reduced doses of R-CHOP, non-anthracycline-based regimens, and non-pegylated liposomal doxorubicin are potential alternative regimens for elderly patients with diffuse large B-cell lymphoma who cannot tolerate standard R-CHOP. Radiation therapy with abbreviated R-CHOP should also be further investigated as a treatment option in this population.

  5. Original Articles

    1. Discipline

      Clinical Trials
      A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52)

      Gunter von Minckwitz, Bettina Conrad, Toralf Reimer, Thomas Decker, Holger Eidtmann, Wolfgang Eiermann, John Hackmann, Volker Möbus, Frederik Marmé, Jochem Potenberg, Elmar Stickeler, Eike Simon, Christoph Thomssen, Jens Huober, Carsten Denkert, Joachim Alfer, Christian Jackisch, Valentina Nekljudova, Nicole Burchardi, Sibylle Loibl and for the German Breast Group Investigators

      Article first published online: 25 JUN 2015 | DOI: 10.1002/cncr.29506

      The results of the ICE II (Investigational Chemotherapy for Elderly patients trial II) trial demonstrated that nonfrail elderly patients with moderate or high-risk breast cancer can be treated with taxane-based polychemotherapy. However, compound-specific toxicities appear to lower relative dose intensity and therefore potential survival benefits.

  6. Correspondence

  7. Original Articles

    1. Discipline

      Folate-mediated one-carbon metabolism genes and interactions with nutritional factors on colorectal cancer risk: Women's Health Initiative Observational Study

      Ting-Yuan David Cheng, Karen W. Makar, Marian L. Neuhouser, Joshua W. Miller, Xiaoling Song, Elissa C. Brown, Shirley A. A. Beresford, Yingye Zheng, Elizabeth M. Poole, Rachel L. Galbraith, David J. Duggan, Nina Habermann, Lynn B. Bailey, David R. Maneval, Marie A. Caudill, Adetunji T. Toriola, Ralph Green and Cornelia M. Ulrich

      Article first published online: 24 JUN 2015 | DOI: 10.1002/cncr.29465

      Evidence from genetic variants suggests that one-carbon metabolism is associated with colorectal cancer risk in postmenopausal women. The essential nutrients in the metabolism (ie, folate, vitamin B6, and vitamin B12) continue to emerge as effect modifiers of genetic influences on colorectal cancer risk.

  8. Commentary

    1. Are high drug prices for hematologic malignancies justified? A critical analysis

      Jagpreet Chhatwal, Michael Mathisen and Hagop Kantarjian

      Article first published online: 23 JUN 2015 | DOI: 10.1002/cncr.29512

      Twenty-nine cost-effectiveness analyses of the treatment of hematologic malignancies published from 1996 to 2012 are evaluated. The current costs of the majority of treatments for hematologic cancers are too high to be deemed cost-effective in the United States.

  9. Original Articles

    1. Discipline

      Population-based trends in high-grade cervical lesions in the early human papillomavirus vaccine era in the United States

      Susan Hariri, Michelle L. Johnson, Nancy M. Bennett, Heidi M. Bauer, Ina U. Park, Sean Schafer, Linda M. Niccolai, Elizabeth R. Unger, Lauri E. Markowitz and HPV-IMPACT Working Group

      Article first published online: 22 JUN 2015 | DOI: 10.1002/cncr.29266

      Significant declines in high-grade cervical lesions in young women since 2008 are likely due to reduced cervical cancer screening but could also reflect vaccine impact. See also pages 000-000.

  10. Editorial

    1. Trends in cervical intraepithelial neoplasia Grade 2+ after human papillomavirus vaccination: The devil is in the details

      Harinder Brar and Allan Covens

      Article first published online: 22 JUN 2015 | DOI: 10.1002/cncr.29264

      Eight years since the introduction of the adolescent HPV vaccination programs, as the vaccinated cohort enters adulthood, the impact of these vaccination programs is now being assessed through surrogate markers such as the incidence of high-grade cervical dysplasia (cytology/histology) and the incidence of genital warts. Early data from the HPV-IMPACT study shows that although there has been a noticeable drop in CIN2+ incidence rates, the results may be confounded by the recent changes in cervical screening guidelines. This study is significant in that it is the first to report on changes in high-grade histological abnormalities in the postvaccination era. Despite the confounding effect of changing cervical cancer screening guidelines, the findings cannot be completely ignored. With wider acceptance and standardization of cervical cancer screening guidelines and with an increasing number of women entering the vaccinated cohort, the magnitude of vaccine effectiveness should become more obvious. Further studies are needed to assess the changes in high-grade histological abnormalities in the post-vaccine era.

  11. Erratum

    1. You have free access to this content
  12. Original Articles

    1. Disease Site

      Breast Disease
      Capecitabine combined with docetaxel versus vinorelbine followed by capecitabine maintenance medication for first-line treatment of patients with advanced breast cancer: Phase 3 randomized trial

      Jiayu Wang, Binghe Xu, Peng Yuan, Fei Ma, Qing Li, Pin Zhang, Ruigang Cai, Ying Fan, Yang Luo and Qiao Li

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29492

      The median progression-free survival and duration of response are longer in patients with advanced breast cancer who receive combined docetaxel and capecitabine chemotherapy compared with those who receive combined vinorelbine and capecitabine. Hand-foot syndrome occurs more frequently in the docetaxel/capecitabine group.

    2. Hematologic Malignancies
      Characteristics of primary splenic diffuse large B-cell lymphoma and role of splenectomy in improving survival

      Osnat Bairey, Lev Shvidel, Chava Perry, Eldad J. Dann, Rosa Ruchlemer, Tamar Tadmor and Neta Goldschmidt

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29487

      Primary splenic diffuse large B-cell lymphoma generally presents with abdominal pain, high lactose dehydrogenase levels, and a splenic mass. Splenectomy at diagnosis improves progression-free and overall survival for patients with early-stage disease.

  13. Editorial

    1. Radiofrequency ablation in high-risk stage I non–small cell lung cancer

      Jessica S. Donington

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29501

      Dupuy et al demonstrate excellent safety, tolerability, and preservation of pulmonary function in this multi-institutional, prospective evaluation of radiofrequency ablation for medically unresectable non–small cell lung cancer. Unfortunately, the rate of local recurrence is 40% at 2 years, and this decreases some enthusiasm for its use in patients who have a radiation or surgical option.

  14. Original Articles

    1. Discipline

      Clinical Trials
      Radiofrequency ablation of stage IA non–small cell lung cancer in medically inoperable patients: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) trial

      Damian E. Dupuy, Hiran C. Fernando, Shauna Hillman, Thomas Ng, Angelina D. Tan, Amita Sharma, William S. Rilling, Kelvin Hong and Joe B. Putnam

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29507

      This highly controlled, National Cancer Institute–funded, multicenter trial shows that radiofrequency ablation can provide safe and effective treatment for patients with medically inoperable early-stage non–small cell lung cancer in a single outpatient session. Thermal ablation should continue to play a role in medically inoperable patients with lung cancer and perhaps in high-risk operable patients currently treated with sublobar resection.

    2. Psychosocial Oncology
      Parenting changes in adults with cancer

      Cynthia W. Moore, Paula K. Rauch, Lee Baer, William F. Pirl and Anna C. Muriel

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29525

      Declines in parenting self-efficacy beliefs after a cancer diagnosis are correlated to aspects of treatment, health-related quality of life, depression and distress, and concerns about the impact of cancer on dependent children. This study highlights the importance of both identifying parenting concerns as a potential mediator between parental cancer and children's heightened risk for psychosocial difficulties and addressing these concerns to alleviate patient distress.

    3. Disease Site

      Head and Neck Disease
      Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer

      Kristina R. Dahlstrom, Guojun Li, Caroline S. Hussey, Jenny T. Vo, Qingyi Wei, Chong Zhao and Erich M. Sturgis

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29538

      Circulating human papillomavirus (HPV) DNA has been detected in patients with carcinoma of the oropharynx. Progression-free survival appears to be better among patients with pretreatment HPV DNA in their tumors and among patients with HPV-positive tumors who are negative for pretreatment serum HPV DNA compared with patients whose tumors are negative for HPV and those whose tumors are positive for HPV who were positive for pretreatment serum HPV DNA, respectively. Circulating HPV DNA does not appear to have clinical usefulness as a marker for disease recurrence in patients with oropharyngeal carcinoma.

  15. Listen to the Patient

    1. Patient perceptions regarding the likelihood of cure after surgical resection of lung and colorectal cancer

      Yuhree Kim, Megan Winner, Andrew Page, Diana M. Tisnado, Kathryn A. Martinez, Stefan Buettner, Aslam Ejaz, Gaya Spolverato, Sydney E. Morss Dy and Timothy M. Pawlik

      Article first published online: 19 JUN 2015 | DOI: 10.1002/cncr.29530

      The objective of the current study was to characterize the prevalence of the expectation that surgical resection of lung or colorectal cancer might be curative. The overwhelming majority of patients undergoing surgery for lung or colorectal cancer believe that the surgery is likely to be curative, even among those patients with advanced stage IV disease. Greater focus on patient-physician engagement, communication, and barriers to discussing goals of care with patients diagnosed with cancer is needed.

  16. Review Articles

    1. Impact of hepatitis C virus eradication on hepatocellular carcinogenesis

      Darrick K. Li and Raymond T. Chung

      Article first published online: 16 JUN 2015 | DOI: 10.1002/cncr.29528

      The rise of direct-acting antivirals heralds an incipient revolution in hepatitis C virus treatment with increasing sustained virological response rates and reductions in hepatitis C virus–associated hepatocellular carcinoma. Epidemiologic and genetic studies are identifying a subpopulation of sustained virological response patients who remain at risk for hepatocellular carcinoma development and would benefit from continued screening.